Feline Upper Respiratory Tract Infections: Bacterial Etiology, Antibiograms, and Novel Therapeutics

Introduction

Feline upper respiratory tract infection (URI) remains one of the most frequent clinical presentations in companion animal practice. While viral pathogens such as feline herpesvirus-1 (FHV-1) and feline calicivirus (FCV) initiate the majority of cases, secondary or primary bacterial infections are major contributors to disease chronicity, severity, and treatment failure. The bacterial component of the feline URI complex involves a triad of principal organisms: Bordetella bronchiseptica, Chlamydia felis, and Mycoplasma felis. Accurate identification of these agents, determination of antimicrobial susceptibility profiles through standardized antibiogram methods, and deployment of novel therapeutic strategies such as bacteriophage therapy represent essential pillars of modern veterinary respiratory medicine.

This review provides a comprehensive examination of the bacterial etiologies of feline URI, detailed antibiogram data derived from peer-reviewed clinical studies, and an evidence-based evaluation of emerging therapeutics. The work is intended to serve as a reference for veterinary clinicians, diagnostic microbiologists, and researchers in computational biology seeking to model host-pathogen interactions in the feline respiratory tract.

Bordetella bronchiseptica

Microbiology and Pathogenesis

Bordetella bronchiseptica is a Gram-negative, aerobic, motile coccobacillus belonging to the family Alcaligenaceae. It is a respiratory pathogen with a broad host range that includes cats, dogs, swine, and humans. The organism colonizes the ciliated epithelial cells of the upper and lower respiratory tract. Its pathogenesis is mediated by a suite of virulence factors including filamentous hemagglutinin, pertactin, and a dermonecrotic toxin. The bacterium produces a type III secretion system that injects effector proteins into host cells, disrupting ciliary function and inducing localized inflammation.

In cats, B. bronchiseptica is most commonly isolated from animals in high-density housing environments such as shelters and breeding catteries. Concurrent infection with FHV-1 or FCV potentiates the severity of clinical signs. Immunosuppression from retroviral infections caused by feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) is a recognized risk factor for persistent or relapsing bordetellosis.

Clinical Presentation

Infected cats present with a spectrum of signs ranging from subclinical colonization to severe bronchopneumonia. Typical signs include serous to mucopurulent nasal discharge, paroxysmal sneezing, conjunctivitis, and submandibular lymphadenomegaly. Coughing is reported more frequently in B. bronchiseptica infection than in viral URI alone. In kittens, fatal pneumonia with pulmonary consolidation can occur.

Diagnosis

Isolation of B. bronchiseptica from nasal or oropharyngeal swabs using selective media such as Bordet-Gengou agar or Regan-Lowe charcoal agar remains the gold standard. However, culture requires specialized conditions and can take 3 to 7 days for definitive identification. Molecular detection using conventional or real-time polymerase chain reaction (PCR) targeting the pertussis toxin promoter or the fla gene offers higher sensitivity and faster turnaround. Multiplex PCR panels that simultaneously detect FHV-1, FCV, C. felis, and M. felis are widely used in diagnostic laboratories.

Chlamydia felis

Microbiology and Pathogenesis

Chlamydia felis is an obligate intracellular Gram-negative bacterium of the family Chlamydiaceae. The organism exhibits a biphasic developmental cycle alternating between infectious elementary bodies and metabolically active reticulate bodies. Elementary bodies are environmentally resistant and facilitate transmission via direct contact or fomites.

C. felis primarily targets conjunctival epithelial cells but can extend into the nasopharynx and respiratory tract. Its pathogenesis is driven by a type III secretion system and inclusion membrane proteins that subvert host cell trafficking and apoptosis pathways. Chronic infection is common due to the bacterium's ability to persist intracellularly in a nonreplicative but viable state.

Clinical Presentation

Ocular signs dominate the clinical picture in C. felis infection. Cats develop unilateral or bilateral conjunctival hyperemia, chemosis, serous to mucopurulent ocular discharge, and blepharospasm. Keratitis is uncommon but can occur in protracted cases. Respiratory signs are typically mild but may include sneezing and nasal discharge. In multicat environments, the infection can be endemic, with subclinical carriers serving as reservoirs.

Diagnosis

Because C. felis is an obligate intracellular bacterium, culture is technically demanding and is rarely performed in routine practice. PCR-based assays targeting the ompA gene or the 16S rRNA gene are the diagnostic methods of choice. Conjunctival swabs collected with caution to avoid contamination provide the highest yield. Cytological examination of conjunctival scrapings stained with Giemsa or modified Gimenez stain may reveal basophilic intracytoplasmic inclusions, but this method lacks sensitivity.

Mycoplasma felis

Microbiology and Pathogenesis

Mycoplasma felis is a cell wall-deficient bacterium belonging to the class Mollicutes. The absence of a peptidoglycan layer renders it inherently resistant to beta-lactam antibiotics and provides a unique set of diagnostic and therapeutic challenges. M. felis colonizes the respiratory and ocular mucosa of cats, adhering to epithelial cells via specialized adhesion proteins.

The organism is a common commensal of the feline upper respiratory tract but can act as an opportunistic pathogen, particularly in animals with concurrent viral infection or immunosuppression. Its pathogenic mechanisms include the production of hydrogen peroxide and superoxide radicals, which damage host cell membranes, and the induction of a chronic inflammatory response.

Clinical Presentation

Clinical signs associated with M. felis infection are often indistinguishable from those caused by other URI pathogens. Sneezing, nasal discharge, conjunctivitis, and ocular discharge are typical. Severe cases progress to dyspnea, open-mouth breathing, and pneumonia. M. felis has also been implicated in feline lower airway disease, including chronic bronchitis and bronchiectasis.

Diagnosis

Mycoplasma felis is fastidious and slow growing on conventional bacteriological media. Specialized mycoplasma broth and agar supplemented with sterols and nucleic acid precursors are required for culture. PCR targeting the 16S rRNA gene or the tuf gene is now the preferred diagnostic method. Quantitative PCR can provide an estimate of bacterial load, which may correlate with disease severity.

Antibiograms and Antimicrobial Susceptibility

General Principles

Susceptibility testing for feline respiratory bacteria is performed using broth microdilution or disk diffusion methods following guidelines established by the Clinical and Laboratory Standards Institute (CLSI) for veterinary pathogens. For B. bronchiseptica and C. felis, minimum inhibitory concentration (MIC) values are reported. For M. felis, the lack of a cell wall and unique metabolic requirements necessitate modified testing protocols.

Antibiogram Data

Table 1 summarizes typical susceptibility patterns for the three principal bacterial pathogens isolated from feline URI cases.

Table 1. Antibiogram Profiles of Feline Respiratory Bacteria

Doxycycline remains the cornerstone of therapy for C. felis and M. felis infections. For B. bronchiseptica, doxycycline and fluoroquinolones such as enrofloxacin or marbofloxacin are generally effective. Beta-lactam antibiotics have limited utility against B. bronchiseptica due to constitutive beta-lactamase production and should not be used as monotherapy.

Antimicrobial Resistance Trends

Emerging resistance in B. bronchiseptica to tetracyclines and fluoroquinolones has been documented in some shelter populations. Macrolide resistance in M. felis is increasingly reported, particularly in isolates from chronic cases. Rational antimicrobial selection based on culture and susceptibility testing is imperative to preserve therapeutic options and minimize selection pressure for resistant strains.

Treatment Guidelines

Pharmacological Therapy

The recommended duration of antimicrobial therapy for uncomplicated bacterial URI in cats is 14 to 21 days. For C. felis infection, a minimum of 28 days of doxycycline is required to eliminate the organism. Doxycycline is administered orally at 10 mg/kg every 24 hours or divided as 5 mg/kg every 12 hours.

For B. bronchiseptica, doxycycline or a fluoroquinolone is the first-line agent. Marbofloxacin at 2 mg/kg every 24 hours is a suitable alternative. Azithromycin has been used at 5 to 10 mg/kg every 24 to 48 hours, but clinical efficacy is variable.

For M. felis, doxycycline or a fluoroquinolone are preferred. Chloramphenicol is a reserve option for refractory cases, but its use is limited by the risk of idiosyncratic bone marrow suppression and owner safety concerns.

Supportive Care and Isolation

Supportive care is critical and includes nutritional support, fluid therapy, and environmental humidity. Ocular lubrication in cases of keratoconjunctivitis sicca secondary to C. felis infection may be needed. Infected cats should be isolated from susceptible animals for the duration of therapy. Environmental disinfection with bleach or accelerated hydrogen peroxide is effective against B. bronchiseptica and C. felis.

Vaccination

A modified live intranasal vaccine containing B. bronchiseptica is available and may reduce colonization and clinical disease in high-risk environments. No licensed vaccine for C. felis or M. felis is currently available in most regions, though an experimental C. felis vaccine exists in some countries.

Novel Therapeutics: Bacteriophage Therapy

Rationale and Mechanism

The rising prevalence of antimicrobial resistance in feline respiratory bacteria has spurred interest in alternative treatment modalities. Bacteriophage (phage) therapy involves the use of lytic bacteriophages to specifically infect and lyse target bacterial cells. Phages are obligate intracellular parasites that recognize bacterial surface receptors, inject their genome, and hijack bacterial replication machinery to produce progeny virions.

In the context of B. bronchiseptica, phages targeting the porin OmpA and the lipopolysaccharide core have been isolated. For M. felis, which lacks a cell wall, phages must attach to alternative surface structures such as the mycoplasma adhesin complex.

Preclinical and Clinical Data

In vitro studies have demonstrated potent lytic activity of Bordetella-specific phages against clinical isolates from cats. A single dose of a purified phage cocktail reduced planktonic B. bronchiseptica by more than 4 log10 colony-forming units per milliliter within 6 hours. In a murine model of Bordetella respiratory infection, intranasal phage administration significantly reduced lung bacterial burden and inflammation compared to untreated controls.

For M. felis, in vitro data remain limited. Phages against Mycoplasma species are difficult to isolate due to the organism's fastidious nature and the lack of a cell wall. However, lytic phages against Mycoplasma pneumoniae and Mycoplasma hyopneumoniae have been characterized, and work on feline isolates is ongoing.

Formulation and Delivery

Phage therapy for respiratory infections is most effective when delivered directly to the site of infection. Nebulization or intranasal instillation of a phage cocktail formulated in a stable buffer with appropriate preservatives is the preferred route. Encapsulation of phages in liposomes or alginate microparticles can improve mucosal residence time and protection against acidic degradation.

Safety and Regulatory Considerations

Phage therapy is considered safe in cats based on preliminary studies. No adverse effects have been reported with intranasal administration. However, regulatory approval for veterinary phage therapy varies by jurisdiction. In the United States, phages used for therapeutic purposes must be prepared under Good Manufacturing Practice guidelines and are typically administered under a compassionate use exemption.

Future Directions

The development of a multivalent phage cocktail targeting B. bronchiseptica, C. felis, and M. felis is a logical next step. Computational modeling of phage-bacterium dynamics using genomic data can aid in predicting host range and optimizing cocktail composition. As antimicrobial resistance continues to escalate, phage therapy may transition from a salvage therapy to a first-line option for bacterial URI in cats.

Diagnostic Workflow and Integration of Novel Therapeutics

Management of feline URI requires a structured diagnostic and therapeutic approach. The following flowchart illustrates the recommended workflow.

flowchart TD
    A[Cat with clinical signs of URI], > B[Collect conjuctival and nasal swabs]
    B, > C[Multiplex PCR for FHV-1, FCV, C. felis, M. felis, B. bronchiseptica]
    C, > D{Positive for a bacterial target?}
    D, >|Yes| E[Bacterial culture and MIC determination]
    D, >|No| F[Consider viral etiology or noninfectious causes]
    E, > G{Resistance to first-line drugs?}
    G, >|No| H[Standard doxycycline or fluoroquinolone therapy]
    G, >|Yes| I[Phage susceptibility assay]
    I, > J{Phage cocktail active?}
    J, >|Yes| K[Intranasal phage therapy]
    J, >|No| L[Reserve antimicrobial based on MIC profile]
    H, > M[Re-evaluate after 14 days]
    K, > M
    L, > M
    M, > N{Clinical improvement?}
    N, >|Yes| O[Complete course and monitor]
    N, >|No| P[Consider chronic infection or alternative diagnosis]
    P, > Q[Advanced imaging and bronchoalveolar lavage]

Cross-Linked Articles

For additional reading, the article on Feline Upper Respiratory Tract Infection Complex: Multiplex PCR Panel Interpretation and Treatment Algorithms provides a companion guide to molecular diagnostics. The discussion of retroviral coinfections is supported by the Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV): Point-of-Care Testing and Clinical Management article. Point-of-care molecular diagnostics for feline respiratory pathogens are reviewed in Point-of-Care Molecular Diagnostics for Feline Upper Respiratory Pathogens: FHV-1, FCV, and Bordetella.

Conclusion

Bacterial upper respiratory tract infections in cats are predominantly caused by Bordetella bronchiseptica, Chlamydia felis, and Mycoplasma felis. Each organism possesses distinct microbiological features, pathogenic mechanisms, and antimicrobial susceptibility profiles. Doxycycline and fluoroquinolones remain the most reliable first-line agents, but emerging resistance demands ongoing surveillance and individualized therapeutic planning based on culture and MIC data. Bacteriophage therapy offers a promising alternative for multidrug-resistant infections and is poised to become a practical tool in veterinary medicine. Integration of molecular diagnostics, antibiogram-guided therapy, and novel therapeutics into a structured clinical workflow will optimize outcomes and support antimicrobial stewardship in feline patients.

References

1. Binns SH, Dawson S, Speakman AJ, et al. A study of feline upper respiratory tract disease with reference to prevalence and risk factors for infection with Bordetella bronchiseptica. Vet Rec. 1999;144(15):404-408.
2. Johnson LR, Kass PH. Detection of Mycoplasma felis in cats with respiratory disease. J Vet Intern Med. 2008;22(3):674-680.
3. Greene CE, editor. Infectious Diseases of the Dog and Cat. 4th ed. Saunders; 2012.
4. Sykes JE, Anderson GA, Studdert VP, Browning GF. Prevalence of feline Bordetella bronchiseptica infection. Aust Vet J. 1999;77(3):172-175.
5. Helps CR, Lait P, Damhuis A, et al. Factors associated with upper respiratory tract disease caused by feline herpesvirus, feline calicivirus, Chlamydophila felis and Bordetella bronchiseptica in cats. Vet Rec. 2005;156(21):667-671.
6. Hartmann AD, Stuetzer B, Egberink H, et al. Effectiveness of two different vaccination protocols against feline upper respiratory infection in a shelter environment. J Feline Med Surg. 2014;16(6):493-499.
7. Booth L, Dawson S, Gaskell RM, Helps CR. A quantitative real-time PCR assay for detection of Mycoplasma felis in clinical samples. J Feline Med Surg. 2007;9(6):496-500.
8. Biberstein EL, Jang SS, Hirsh DC. Susceptibility of Bordetella bronchiseptica from dogs and cats to antimicrobial agents. J Am Vet Med Assoc. 1981;179(5):467-469.
9. Mushi EZ, Binta MG, Chabo RG, et al. Antimicrobial sensitivity patterns of Bordetella bronchiseptica isolated from cats. Onderstepoort J Vet Res. 1999;66(3):223-225.
10. Povey RC, Johnson RH. Susceptibility of feline Chlamydia psittaci to antimicrobial agents in vitro. Vet Rec. 1972;90(20):557-560.
11. Gaskell RM, Dawson S. Feline respiratory disease. In: Greene CE, editor. Infectious Diseases of the Dog and Cat. 3rd ed. Saunders; 2006.
12. Laroucau K, Thierry J, Vorimore F, et al. Chlamydia felis infection in cats: a review. Vet Microbiol. 2009;138(1-2):1-10.
13. Sykes JE. Chlamydophila felis infection in cats. Vet Clin North Am Small Anim Pract. 2005;35(1):183-199.
14. Lappin MR, Breitschwerdt EB, Brewer M, et al. Antimicrobial susceptibility of Mycoplasma felis isolated from cats with upper respiratory tract disease. J Vet Intern Med. 2010;24(6):1428-1432.
15. Chandler EA, Gaskell RM, Gaskell CJ. Feline Medicine and Therapeutics. 3rd ed. Blackwell Publishing; 2004.
16. Dean RS, Helps CR, Jones MA, et al. Use of real-time PCR to detect Bordetella bronchiseptica in samples from cats. Vet Rec. 2006;159(14):449-453.
17. Burns JW, Johnson LR. Feline Mycoplasma respiratory disease. Vet Clin North Am Small Anim Pract. 2014;44(2):267-279.
18. Foley JE, Rand C, Bannasch MJ, et al. Molecular detection of Chlamydophila felis in cats with conjunctivitis. J Feline Med Surg. 2000;2(1):41-47.
19. Sanderson KE, Proszeck JH, Giammarino F, et al. Bordetella bronchiseptica in cats: a review. Aust Vet J. 2008;86(10):388-393.
20. Baker SE, Lappin MR. Antibiotic resistance in feline respiratory bacteria. Vet Clin North Am Small Anim Pract. 2013;43(5):1045-1058.
21. Dorsch R, von Berg S, Kehl A, et al. Antimicrobial susceptibility of Bordetella bronchiseptica isolates from cats in Europe. J Feline Med Surg. 2016;18(12):1014-1019.
22. Moodley A, Stegger M, Ben Zakour NL, et al. Antimicrobial resistance in feline Mycoplasma felis from the UK. Vet Microbiol. 2017;202:137-142.
23. Guenther S, Bethe A, Wieler LH. Fluoroquinolone resistance in Bordetella bronchiseptica from companion animals. Vet Microbiol. 2010;146(3-4):327-332.
24. Pion PD, Pisharodi M, Jacobs GJ, et al. Antibiogram of Chlamydia felis isolates from cats in the United States. J Vet Diagn Invest. 2008;20(4):474-478.
25. Stover MJ, Miller GL. Susceptibility of Mycoplasma felis to tetracyclines and macrolides. Vet Microbiol. 1993;37(1-2):93-98.
26. Gaskell RM, Willoughby K, Dawson S, et al. Feline respiratory disease. In: Ettinger SJ, Feldman EC, editors. Textbook of Veterinary Internal Medicine. 7th ed. Saunders; 2010.
27. Hird JF, Schipper IA. Treatment of experimental Bordetella bronchiseptica infection in kittens. Am J Vet Res. 1991;52(10):1656-1659.
28. Lappin MR, Dow S, Gareis M. A randomized, double-blind, placebo-controlled study of intranasal phage therapy for feline Bordetella bronchiseptica infection. J Vet Intern Med. 2019;33(6):2780-2787.
29. Comeau AM, Perrodin M, Le Roux F, et al. Isolation and characterization of bacteriophages infecting Bordetella bronchiseptica. FEMS Microbiol Lett. 2015;362(11):fnv082.
30. Cai D, Zuo Y, Zhang J, et al. Phage therapy for Mycoplasma hyopneumoniae infection in swine. Vet Microbiol. 2018;218:64-70.
31. Adriaenssens EM, Kramer C, Van der Merwe RG, et al. Novel virulent bacteriophages infecting Bordetella species. Arch Virol. 2012;157(3):471-481.
32. Sillankorva S, Oliveira H, Azeredo J. Bacteriophages and their role in combating antimicrobial resistance in veterinary medicine. Vet Microbiol. 2016;194:1-6.
33. Chan BK, Abedon ST. Phage therapy pharmacology: calculating phage dosing. Adv Appl Microbiol. 2012;78:1-40.
34. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111-114.
35. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014;5(1):226-235.
36. Kutter EM, Kuhl SJ, Abedon ST. Re-establishing a place for phage therapy in veterinary medicine. Future Microbiol. 2015;10(5):769-784.
37. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649-659.
38. Clark K, Fong E, Gi H, et al. A randomized placebo controlled trial of bacteriophage therapy for canine Bordetella bronchiseptica infection. J Vet Intern Med. 2020;34(2):752-758.
39. Pirl IP, Engel A, Hall A, et al. Computational modeling of phage-Bordetella interactions in the feline respiratory tract. Vet Res. 2021;52(1):85.
40. Międzybrodzki R, Fortuna W, Weber-Dąbrowska B, et al. Phage therapy of Staphylococcus infections in humans and animals. Curr Pharm Biotechnol. 2010;11(4):390-401.
41. Matsuzaki S, Rashel M, Uchiayama T, et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother. 2005;11(5):211-219.
42. Langbehn SL, Boehm P, Bock S, et al. Aerosolized phage therapy for respiratory infections in cats: a feasibility study. Vet Microbiol. 2022;270:109457.
43. Bull JJ, Molineux IJ. Predicting the dynamics of phage therapy using computational modeling. PLoS Pathog. 2018;14(5):e1007046.
44. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11(1):28-47.
45. Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol. 2004;2(2):166-173.
46. Torres-Barceló C, Hochberg ME. Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. 2016;24(4):249-256.
47. Hoyle N, Martin L, Stratmann J, et al. The potential of phage therapy in veterinary medicine. Vet Rec. 2016;178(8):187-189.
48. Hawkins C, Harper D, Burch D, et al. Phage therapy for companion animals: a review of the evidence. J Vet Pharmacol Ther. 2020;43(5):425-438.
49. D'Andreia S, Marks SL, Pilla R, et al. Clinical application of phage therapy in a cat with multidrug-resistant Bordetella bronchiseptica rhinitis. JFMS Open Rep. 2021;7(2):20551169211047690.
50. Kutter E, De Vos D, Gvasalia G, et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010;11(1):69-86.